Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

878
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
878
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

989
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
989
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.1K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.1K
Neural Regulation01:37

Neural Regulation

43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.2K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-ancestry analysis of <i>POLG</i> variants in Parkinson's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Insights from a cross-sectional population-based study of 10,929 Australians living with Parkinson's disease: risk factors, comorbidities, and sex differences.

The Lancet regional health. Western Pacific·2026
Same author

MDSGene Systematic Review of Common Forms of Dominant Hereditary Spastic Paraplegia: Novel Insights.

Movement disorders clinical practice·2026
Same author

Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target.

Annals of neurology·2026
Same author

Liver Involvement in POLG Disease-a Multicentre Cohort Study of 202 Patients.

Journal of inherited metabolic disease·2025
Same author

PARKIN protein-deficient iPSC line (FINi006-A) from an early-onset Parkinson's disease female patient.

Stem cell research·2025
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
Same journal

Brain-first versus body-first Parkinson's disease: Differential findings on pupillary, brainstem and vagus sonography.

Journal of neurology·2026
Same journal

Spontaneous intracranial hypotension due to pelvic cerebrospinal fluid leak.

Journal of neurology·2026
Same journal

Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.

Journal of neurology·2026
Same journal

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026
Same journal

Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.

Journal of neurology·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.3K

Gastrointestinal dysfunction in Parkinson's disease.

Michal Lubomski1,2,3, Ryan L Davis4, Carolyn M Sue5,4

  • 1Department of Neurology, Clinical Admin 3E, Level 3, ASB, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, 2065, Australia. mlub6241@uni.sydney.edu.au.

Journal of Neurology
|January 29, 2020
PubMed
Summary
This summary is machine-generated.

Gastrointestinal dysfunction is common in Parkinson's disease (PD), with patients experiencing more severe constipation and indigestion than healthy individuals. Early recognition of these GI issues can improve patient care and management.

Keywords:
ConstipationDysmotilityGastrointestinal dysfunctionGastroparesisParkinson’s disease

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.3K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Area of Science:

  • Neurology
  • Gastroenterology
  • Clinical Research

Background:

  • Gastrointestinal (GI) dysfunction is a frequent and impactful comorbidity in Parkinson's disease (PD).
  • GI symptoms manifest across the disease spectrum, affecting quality of life and treatment strategies.
  • This study quantifies real-world differences in GI symptom frequency and severity between PD patients and healthy controls (HC).

Purpose of the Study:

  • To compare the prevalence and severity of gastrointestinal symptoms in Parkinson's disease patients versus healthy controls.
  • To investigate the relationship between GI dysfunction, chronic pain, physical activity, and Parkinson's disease therapies.

Main Methods:

  • A cohort of 103 Parkinson's disease patients was compared with 81 healthy control subjects.
  • Validated questionnaires assessed constipation severity, upper and lower GI symptoms, and physical activity levels.
  • Statistical analyses were performed to identify significant differences and correlations.

Main Results:

  • Parkinson's disease patients were three times more likely to report constipation (78.6% vs 28.4%) with fourfold increased severity and harder stools.
  • Indigestion, nausea, excessive fullness, and bloating were significantly higher in PD patients, indicated by elevated Leeds Dyspepsia Questionnaire scores.
  • Chronic pain, more prevalent in women, correlated with constipation and upper GI issues. Physical activity was reduced in PD patients and correlated with constipation severity. PD therapies were linked to increased fullness, bloating, and harder stools.

Conclusions:

  • Parkinson's disease patients exhibit significantly more prevalent and severe gastrointestinal dysfunction, even in later disease stages.
  • Early identification of GI dysfunction in PD allows for targeted management of chronic pain and constipation.
  • Optimizing patient care involves promoting physical activity and rationalizing Parkinson's disease therapies to mitigate GI side effects.